Dechra Pharmaceuticals PLC Director/PDMR Shareholding (7504Z)
16 January 2024 - 3:51AM
UK Regulatory
TIDMDPH
RNS Number : 7504Z
Dechra Pharmaceuticals PLC
15 January 2024
15 January 2024
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that following the Court
sanctioning the Scheme at the Sanction Hearing on 12 January 2024,
the following PDMRs acquired ordinary shares of 1p each in the
Company pursuant to awards granted to them under the Dechra
Pharmaceuticals PLC Long Term Incentive Plan (the LTIP), the
Deferred Bonus Plan 2021 and the Global Save As You Earn Plan 2018
(SAYE) as detailed in the tables below. All shares were subject to
the Cash Offer of the Company at GBP38.75 per share:
Long Term Incentive Plan, SAYE and Deferred Bonus Plan
Name Capacity Date of Grant Award Cost Shares Acquired
& Sold
22 September
Ian Page Director 2020* Qualifying LTIP* Nil 5,372
22 September
Ian Page Director 2020* Qualifying CSOP GBP32.37 155
16 September
Ian Page Director 2021 LTIP** Nil 18,551
9 September
Ian Page Director 2022 LTIP ** Nil 20,193
20 September Deferred Bonus
Ian Page Director 2022 Plan Nil 3,580
19 October
Ian Page Director 2020 SAYE GBP28.68 627
22 September
Paul Sandland Director 2020* LTIP* Nil 2,335
16 September
Paul Sandland Director 2021 LTIP** Nil 8,600
9 September
Paul Sandland Director 2022 Qualifying LTIP** Nil 9,983
9 September Qualifying CSOP
Paul Sandland Director 2022 +/- GBP31.99 227
20 September Deferred Bonus
Paul Sandland Director 2022 Plan Nil 2,293
19 October
Paul Sandland Director 2020 SAYE GBP28.68 627
*The vesting of the awards was subject to the achievement of
performance conditions which were satisfied to the extent that the
awards vested at 16.4%.
Ian Page exercised the linked tax qualifying option at an
exercise price of GBP32.37 as part of his LTIP award. 25 nil cost
options were forfeited to the value of that gain.
** Both the EPS and ROCE performance conditions for LTIP awards
granted in 2021 and 2022 were deemed to have been met as detailed
in the Co-Operation Agreement between the Company and Freya Bidco
Limited. The TSR performance conditions was measured for both
awards. The awards taking into account all of the performance
conditions vested at 90.8% for the 2021 grant and 100% for the 2022
grant. Both awards were pro rata for time.
+/- Paul Sandland exercised the linked tax qualifying option at
an exercise price of GBP31.99 as part of his LTIP award. 39 nil
cost options were forfeited to the value of that gain.
Deferred Bonus Plan 2021 (Cash Settled)
Ian Page and Paul Sandland were granted on 18 October 2023,
1,080 and 715 awards respectively under the Deferred Bonus Plan
2021. These were cash settled in accordance with the Co-Operation
Agreement between the Company and Freya Bidco Limited.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the UK Market Abuse
Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 5,372
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
------------------------------------ ----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------ ----------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
------------------------------------ ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP32.37 155
------------------------------------ ------------------- -------------------
d) Aggregated information
* Aggregate volume
155
GBP32.37
* Price GBP5,017.35
* Total
------------------------------------ ----------------------------------------
e) Date of the transaction 2024.01.15
------------------------------------ ----------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 18,551
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 20,193
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Deferred Bonus Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 3,580
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
------------------------------------ ------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------ ------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ------------------------------------------
3. Details of the Issuer
--------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ------------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Global Save As You Earn Plan
------------------------------------ ------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP28.68 627
------------------------------------ -------------------- --------------------
d) Aggregated information
* Aggregate volume
627
GBP28.68
* Price GBP17,982.36
* Total
------------------------------------ ------------------------------------------
e) Date of the transaction 2024.01.15
------------------------------------ ------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 2,335
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 8,600
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 9,983
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
------------------------------------ ----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------ ----------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
------------------------------------ ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP31.99 227
------------------------------------ ------------------- -------------------
d) Aggregated information
* Aggregate volume
227
GBP31.99
* Price GBP7,261.73
* Total
------------------------------------ ----------------------------------------
e) Date of the transaction 2024.01.15
------------------------------------ ----------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Deferred Bonus Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 2,293
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
* Total
---------------------------------- ----------------------------------------
e) Date of the transaction 2024.01.15
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
------------------------------------ ------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------ ------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ------------------------------------------
3. Details of the Issuer
--------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ------------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Global Save As You Earn Plan
------------------------------------ ------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP28.68 627
------------------------------------ -------------------- --------------------
d) Aggregated information
* Aggregate volume
627
GBP28.68
* Price GBP17,982.36
* Total
------------------------------------ ------------------------------------------
e) Date of the transaction 2024.01.15
------------------------------------ ------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ------------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBLGDBUSBDGSU
(END) Dow Jones Newswires
January 15, 2024 11:51 ET (16:51 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2023 to Apr 2024
